Recent news on Exubera

Nektar to Lay Off 25 Percent of Workers  -  25 May 2007
Houston Chronicle,...based company helped develop the inhalable insulin Exubera with Pfizer Inc. and Sanofi-Aventis SA. Pfizer, which bought out the rights from Sanofi-Aventis,

Pfizer's LaMattina Is Rewarded Handsomely  -  25 May 2007
TheDay,Regulators have also rejected applications for drugs for osteoporosis and pain, and a new inhaled insulin product called Exubera is selling far more slowly

MannKind's hopes rest with its inhaled insulin  -  May 21, 2007
Los Angeles Times,A competing drug, Pfizer Inc.'s Exubera, the first FDA-approved inhaled insulin, has had lackluster sales since debuting last year.

Sour Results for Nektar  -  May 14, 2007
Motley FoolEven with an extra 60 days worth of Exubera revenue due to this accounting change, Nektar still posted a loss of $26 million this quarter.

Pfizer's head of research is departing  -  May 21, 2007
International Herald Tribune,Meanwhile, Exubera, an inhaled insulin, has sold far less than the company had expected. Still, Pfizer has had some successes recently, including Sutent,

Pfizer’s Head of Research Is Departing  -  May 20, 2007
New York Times,And Exubera, an inhaled insulin, has sold far more slowly than the company expected. Still, the company has had some successes recently, including Sutent,

Inhaled Insulin May Help Diabetes Control  -  May 13, 2007
6abc.com,He, and other doctors nationwide, are studying Exubera to see if it will help patients already on injected insulin keep blood sugar levels more even,

Nektar Therapeutics decides on India as second R&D hub  -  May 4, 2007
Moneycontrol.com,The company, which has brought to the global market the world's first inhaled (powder) drug to treat diabetes (Exubera) with Pfizer, will build a modern

Sanofi reports low Q1 profits  -  May 3, 2007
CNN International...hit by the absence of a one-off gain last year from the disposal of Sanofi's interest in inhaled insulin drug Exubera to Pfizer Inc..

Sanofi-Aventis reports lower first-quarter profits  -  May 3, 2007
International Herald Tribune,...€1.62 in the first quarter of 2006, when Sanofi-Aventis booked a one-off gain from selling the rights to inhaled insulin product Exubera to Pfizer Inc.

EARNINGS WATCH Updates, advisories and surprises  -  May 2, 2007
MarketWatch...or 1.62 euros a share, in the year-ago quarter, when the company booked a one-off gain from the sale of its inhaled insulin product Exubera.

Sanofi lifts year outlook despite lower Q1 profits  -  May 2, 2007
Reuters...hit by the absence of a one-off gain last year from the disposal of Sanofi's interest in inhaled insulin drug Exubera to Pfizer Inc. (PFE.

Bespak expects in line results  -  May 3, 2007
Business Weekly,...won a number of new valve and dose counter development programmes during the year and had seen continued benefit from demand for the Exubera inhaler.

Bespak sees FY performance in line with or marginally beating ...  -  May 3, 2007
Hemscott,...and dose counter programmes during the year, Bespak said there were uncertainties about short- to medium-term sales volumes of its Exubera inhaler.

What Diabetes Patients Need to Know  -  May 21, 2007
Wall Street Journal (subscription),The oldest drug for diabetes is insulin, which is typically injected, though Pfizer Inc.'s Exubera form is inhaled. M. Angelyn Bethel, at endocrinologist at

2 officers at Pfizer leaving by year’s end  -  May 21, 2007
Providence Journal (subscription),...court ruling accelerated generic competition to Norvasc and sales of the inhaled insulin treatment Exubera missed targets, the company said April 20.

West Pharmaceutical Services Announces First Quarter 2007 Results  -  Apr 26, 2007
PR-Inside.com (Pressemitteilung),Sales from Pfizer's Exubera(R) Inhalable Insulin device contributed a $6.6 million increase as initial commercial production of the device occurred during

Pfizer R&D President To Retire, CFO Resigns  -  May 20, 2007
Trading Markets,Disappointing revenue performance of Exubera, inhaled insulin, was another setback. The drug did not gain acceptance on concerns over long-term lung safety

The Total Number of Diabetes Patients in the World is Expected to ...  -  May 18, 2007
Business Wire (press release),Inhaled Insulin devices were earlier thought to make a big success, but Pfizer’s Exubera was a big flop in 2006 with estimated revenues of 1/10th as what

Surge expected for diabetes drug market  -  May 17, 2007
CNNMoney.comPfizer's (down $0.01 to $27.31, Charts, Fortune 500) Exubera, the first form of insulin to be inhaled instead of injected, has had such a lackluster market

Stem Cell Therapy: A Ray of Hope for Diabetics and Researchers  -  26 Apr 2007
PressZoom (press release),For example, Exubera – the world’s 1st and perhaps only inhaled insulin product developed by Pfizer – was once seen as a potential breakthrough drug.

West Pharmaceutical Services Announces First Quarter 2007 Results  -  26 Apr 2007
PR Newswire (press release),Sales from Pfizer's Exubera(R) Inhalable Insulin device contributed a $6.6 million increase as initial commercial production of the device occurred during

A Few Lessons From Exubera  -  Apr 18, 2007
Seeking Alpha,Fredric Cohen (Pharma's Cutting Edge) submits: As you might have read in papers like the International Herald Tribune, Exubera, the first marketed inhaled

Exubera has opened door for pulmonary delivery growth  -  Apr 16, 2007
OutSourcing-Pharma.com,16/04/2007 - While the market performance of Exubera may have fallen short of expectations, Pfizer's inhaled insulin has opened the door for a wider variety

The drug Exubera looks like an expensive flop for Pfizer  -  Apr 10, 2007
International Herald Tribune,NEW YORK: Exubera, the first and so far only commercially available inhaled-insulin diabetes treatment, is on the verge of turning into an expensive flop

Pfizer: Research Staff Layoffs and Exubera Relaunch  -  Apr 12, 2007
Seeking Alpha,Looks like my doubts about the potential of Pfizer's inhaled insulin Exubera were well-founded. Pfizer's having some trouble making headway,

Lower Exubera Projections Bad News For Pfizer, Nektar  -  Apr 5, 2007
Seeking Alpha,Notable Calls submits: Merrill Lynch is lowering their EPS projections on Pfizer (NYSE:PFE) to reflect dramatically lower Exubera projections and early

MEREDITH CUMMINGS: I’m quitting Exubera  -  Apr 5, 2007
Tuscaloosa News (subscription),So when I tell you about my latest experience with Exubera, you’ll understand why I have to give up. I’ve been beat. I give in.

MEREDITH CUMMINGS: Exubera and I had a rough start  -  Mar 29, 2007
Tuscaloosa News (subscription),...sOnly a couple of days after I giddily started to use Exubera, the new inhaled insulin by Pfizer, I started having some mild problems.

Pfizer sees 17 percent profit decline  -  Apr 20, 2007
Trenton Times,..."Exubera is not where we wanted it to be at this time," said Jeffrey Kindler, chairman and chief executive, in a conference call.

Pfizer Inc has said its profit fell 17.5 per cent in the first ...  -  Apr 20, 2007
NDTV.com,Sales of the inhalable insulin Exubera, however, were disappointing, the company said, not specifying dollar amounts. "Exubera is not where we wanted it to

Pfizer Earnings Fall on Drop in Norvasc, Zoloft Sales (Update5)  -  Apr 20, 2007
Bloomberg...``The impact of generic Norvasc, coupled with increased promotional spending around Exubera, are contributing to a greater decline then we would have

Pfizer 1Q profit falls 18 percent  -  Apr 20, 2007
Kansas City Star,Sales of the inhalable insulin Exubera, however, were "disappointing," the company said, not specifying dollar amounts. The overall results were well above

Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full ...  -  Apr 20, 2007
PharmaLive.com (press release),For example, while we remain convinced that Exubera offers substantial benefit for diabetic patients worldwide, we are disappointed with the product’s

Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full ...  -  Apr 20, 2007
Genetic Engineering News (press release),For example, while we remain convinced that Exubera offers substantial benefit for diabetic patients worldwide, we are disappointed with the product's

Pfizer 1Q profit falls 17.5 percent  -  Apr 20, 2007
Kentucky.com,Sales of the inhalable insulin Exubera, however, were "disappointing," the company said, not specifying dollar amounts. First-quarter results were well

Pfizer Reports 17.5% Decline in Profit  -  Apr 20, 2007
New York Times,Sales of the inhalable insulin Exubera were “disappointing,� the company said, not specifying dollar amounts. The company seeks to develop the market for

Pfizer 1st-quarter profit falls 17.5 percent on charges  -  Apr 20, 2007
San Diego Union Tribune,Sales of the inhalable insulin Exubera, however, were “disappointing,� the company said, not specifying dollar amounts. First-quarter results were well

Pfizer Drug for Diabetes Is Lagging  -  Apr 9, 2007
New York Times,Exubera, the first and so far only commercially available inhaled-insulin diabetes treatment, is on the verge of turning into an expensive failure for its

Pfizer 1st-quarter profit falls sharply  -  Apr 20, 2007
MSNBCSales of the inhalable insulin Exubera, however, were "disappointing," the company said, not specifying dollar amounts. The results were well above Wall

Pfizer 1Q profit falls 18 percent  -  Apr 20, 2007
White Rock Reviewer,Sales of the inhalable insulin Exubera, however, were "disappointing," the company said, not specifying dollar amounts.

Pfizer's Inhaled-Insulin Diabetes Drug Falters in Domestic Sales  -  Apr 9, 2007
The MIT Tech,Exubera, the first and so far only commercially available inhaled-insulin diabetes treatment, is on the verge of turning into an expensive flop for its

Pfizer's profit drops on charges  -  Apr 20, 2007
MarketWatchPfizer also said that it was disappointed with the performance so far of its inhaled insulin product, Exubera. Pfizer said that the product,

Pfizer earnings squeezed  -  Apr 20, 2007
CNNMoney.comBut results beat expectations, despite sooner-than-expected loss of blockbuster Norvasc, weak Exubera sales. By Aaron Smith, CNNMoney.com staff writer

Pfizer 1st-Quarter Profit Falls 18 Pct.  -  Apr 20, 2007
Forbes,Sales of the inhalable insulin treatment Exubera were "disappointing," the company said, not specifying dollar amounts. Pfizer said the updated guidance

New inhalant insulin therapy available on Guam  -  Apr 22, 2007
KUAM.com,The new insulin therapy is called Exubera, which is new to Guam and some parts of the US mainland. Said Akimoto, "People with diabetes are regularly

Pfizer 1st-quarter profit falls 18 percent on 1-time charges, weak ...  -  Apr 20, 2007
International Herald Tribune,...said Friday its profit fell 18 percent in the first quarter, hurt by one-time charges and disappointing sales of diabetes drug Exubera.

Pfizer earnings fall  -  Apr 20, 2007
CNNMoney.comProfits fall 18 percent on disappointing sales of Exubera and increasing competition with generics; stock eases 2 percent.

Sales of Pfizer’s diabetes inhaler disappoint  -  Apr 12, 2007
Business Online,PFIZER, the world’s biggest pharmaceutical company, is close to another high-profile disappointment with Exubera, its inhaled insulin treatment for diabetes

Pfizer 1st-quarter profit falls 18 pct.  -  Apr 20, 2007
Hemscott,Sales of the inhalable insulin treatment Exubera were 'disappointing,' the company said, not specifying dollar amounts. Pfizer said the updated guidance

Pfizer earnings fall  -  Apr 20, 2007
Asbury Park Press,Sales of the inhalable insulin treatment Exubera were "disappointing,'' the company said, not specifying dollar amounts. Pfizer said the updated guidance

Pfizer first-quarter profit tumbles 17pc  -  Apr 21, 2007
Gulf Daily News,...largest drug-maker, said its profit fell 17.5 per cent in the first quarter, hurt by one-time charges and disappointing sales of diabetes drug Exubera.

Inhaled Insulin Fails to Impress  -  Apr 1, 2007
Press-Enterprise (subscription),Exubera, a powdered form of insulin inhaled through a special device, was introduced last year in a targeted launch to specialists, a debut analysts deemed

Earnings Snapshots  -  Apr 21, 2007
Salt Lake Tribune,...largest drug maker said its profit fell 18 percent in the first quarter, hurt by one-time charges and disappointing sales of diabetes drug Exubera.

Pfizer 1st-quarter profit falls 17.5 percent on charges; outlook ...  -  Apr 21, 2007
Therapeutics Daily (subscription) (press release),...largest drug maker, said its profit fell 17.5 percent in the first quarter, hurt by one-time charges and disappointing sales of diabetes drug Exubera.

ANALYSIS-Pfizer's Inhaled-Insulin Struggles May Haunt Class  -  Apr 10, 2007
Reuters.uk,N: Quote, Profile , Research) new inhaled insulin, Exubera, are off to such a sluggish start that the launch has cast doubts on the company's ability to hit

Pfizer's inhaled-insulin struggles may haunt class  -  Apr 10, 2007
ReutersN: Quote, Profile, Research) new inhaled insulin, Exubera, are off to such a sluggish start that the launch has cast doubts on the company's ability to hit

Lilly still breathing in inhaler pursuit  -  Mar 31, 2007
Indianapolis Business Journal,Pfizer was ramping up production there of Exubera, its new inhaled insulin product. Lilly, meanwhile, knew it wouldn’t have a competing product on the

Pfizer Q1 profits fall by 17.5pc  -  Apr 20, 2007
Unison.ie (subscription),...said yesterday its profit fell 17.5pc in the first quarter, hurt by one-time charges and disappointing sales of diabetes drug Exubera.

Sector Glance: Pharmaceuticals  -  Apr 20, 2007
Forbes,Pfizer (nyse: PFE - news - people )'s profit dropped 17 percent due to weaker sales of Exubera, an inhalable form of insulin, and charges related to

Pfizer’s inhaled insulin fails to impress  -  27 Mar 2007
East Valley Tribune,Exubera, a powdered form inhaled through a special device, was introduced last year in a targeted launch to specialists, a debut analysts deemed

Foulkes: Accountants enormously important to civilization  -  27 Mar 2007
Terre Haute Tribune Star,For example, officials at Pfizer apparently calculated that the raw materials, scientists, engineers, and other resources necessary to produce Exubera,

Dr. White Answers Your Medication Questions  -  Mar 24, 2007
Diabetes Interview,At present, Exubera requires that patients have their lung function tested and then re-tested six months later to make sure that there is no damage to lung

Inhaled Insulin A Tough Sell  -  Mar 21, 2007
Hartford Courant,Exubera, a powdered form inhaled through a special device, was introduced last year in a targeted launch to specialists, a debut that analysts deemed

Pfizer's inhaled insulin hasn't taken off  -  Mar 21, 2007
commercialappeal.com (subscription),New York physician Robert Fafalak says his patients have been helped by Pfizer's Exubera, which delivers insulin through an inhaler. By Theresa Agovino

Doctors, insurers shrug off drug  -  Mar 22, 2007
Indianapolis Star,Exubera, a powder inhaled through a special device, was introduced in September in a targeted launch to specialists, a debut analysts deemed disappointing.

County Council approves $4.515M TIF bond for Pfizer  -  Mar 21, 2007
Terre Haute Tribune Star,TERRE HAUTE — Pfizer has cut a temporary work force and reduced its total production days as it stockpiles Exubera, a powdered form of insulin.

Inhalable insulin has yet to catch on  -  Mar 21, 2007
Newark Star Ledger,Exubera, a powdered form in haled through a special device, was introduced last year in a targeted launch to specialists, a debut analysts deemed

MEREDITH CUMMINGS: Inhaled insulin passes test with flying colors  -  Mar 22, 2007
Tuscaloosa News (subscription),Then, I tell him he has to try Exubera. This is the new inhaled insulin that I finally got to try last week after anticipating for 21 years a way to treat

Terre Haute official worried about Pfizer insulin project  -  Mar 22, 2007
Indianapolis Business Journal,Pfizer hired nearly 400 full-time workers last year to build inventories in anticipation of launching the powder, called Exubera.

Busted? More Bad News for Pfizer's Exubera  -  Mar 1, 2007
Brandweek Magazine,NEW YORK -- The news for Pfizer’s Exubera just keeps getting worse: Today Friedman, Billings, Ramsey analyst Jim Reddoch published numbers that suggest

Pfizer's a Sell: Shrinking Top Line, No Blockbusters In the Pipeline  -  Mar 22, 2007
Seeking Alpha,Exubera received approval in late January 2006 and launch in the US in September 2006. The drug launched in overseas market such as German and Ireland in

Top Health Stories For March 22, 2007  -  Mar 22, 2007
WVNS-TV,Introduced last year, Exubera offers diabetics an alternative to needles. The drug proved safe in testing, but some specialists are concerned about possible

Medical Minute  -  Mar 22, 2007
KHQA,Exubera offers diabetics an alternative to needles. In testing the drug proved safe, but some specialists are concerned about possible long term effects

Pfizer promoting inhaled insulin  -  Mar 22, 2007
Daily Press,Exubera, a powdered form inhaled through a special device - shown above by Dr. Robert Fafalak in his New York office - was introduced last year in a

No More Needles  -  Mar 22, 2007
WMDT,Sufferers can now breathe their insulin in through the first inhaled diabetes treatment, an inhaler called "Exubera." Researchers say the drug hasn't been

Pfizer Taking Some Hits Over Billion-Dollar Bong  -  Feb 26, 2007
Brandweek Magazine,NEW YORK -- Last year, Pfizer paid Sanofi-Aventis $1.4 billion for Exubera, a new inhaled insulin product for diabetics that Pfizer forecast would produce

Evolution of a Pulmonary Insulin Delivery System for Patients With ...  -  Mar 6, 2007
Medscape (subscription)Within-subject variability of inhaled insulin (Exubera) versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus.

Inhaled insulin not in high demand  -  Mar 16, 2007
WVEC.com (subscription),A pain-free alternative to insulin injections came last year when the Food and Drug Administration approved Exubera, the first inhalable insulin.

MEREDITH CUMMINGS: Inhaler is large and awkward  -  Mar 15, 2007
Tuscaloosa News (subscription),The receptionist said I could come in that day to learn how to use Exubera, the inhaled insulin now available for diabetics to control their blood sugar.

BREATHING TREATMENT: Inhaled insulin gives diabetics a choice  -  Mar 7, 2007
New Albany Tribune,In 2006, the US Food and Drug Administration approved Exubera, a form of inhaled insulin. Instead of patients having to give themselves injections prior to

News Analysis: Pfizer Taking Some Hits Over 'Billion-Dollar Bong'  -  Feb 25, 2007
Brandweek Magazine,Now, few observers outside Pfizer believe that Exubera can reach its $2 billion benchmark, a target the company repeated to analysts in January.

Nektar Announces Financial Results for the Year and Fourth Quarter ...  -  Mar 1, 2007
PharmaLive.com (press release),In addition, we are excited about the positive response of patients on Exubera, the most important innovation in insulin delivery in the last 80 years.

Health Matters: HeartMath adds up to heart help  -  Mar 8, 2007
Terre Haute Tribune Star,Pfizer Inc.’s inhaled insulin, Exubera, has taken a hit in both the Feb. 26 and March 1 issues of Brandweek, a publication that focuses on branding and

Aradigm Focuses on Inhaled Drugs  -  Mar 9, 2007
Seeking Alpha,Exubera has not met analysts’ projections for its revenue, mainly because insurance companies have been unwilling to pay more for inhaled insulin than they

Smart drug devices  -  Mar 25, 2007
Express Pharma,Developed in a joint effort by Aventis and Pfizer, Exubera is an insulin rDNA origin powder for oral inhalation. Indicated for the treatment of adults with

Taurel predicts flat Zyprexa sales  -  Mar 15, 2007
Indianapolis Business Journal,Taurel also said Lilly is closely watching Pfizer Inc. to learn from mistakes it is making launching its Exubera inhaled insulin. Lilly plans to introduce

MEREDITH CUMMINGS: Pulmonary function test scary for this diabetic  -  Mar 1, 2007
Tuscaloosa News (subscription),I’m still waiting to see if I passed my test to be able to try Exubera. But if history is any indication, I probably did middle-of-the-road OK.

Drugs firms reportedly ready anti-diabetes launches in India  -  Mar 2, 2007
MarketWatchPfizer plans to launch Exubera, an insulin that can be inhaled, and has received necessary regulatory approvals, the report said.

Pfizer is up off the mat -- now is the time to move  -  Mar 22, 2007
Blogging StocksRecently approved compounds on the Pfizer marketing list include: Exubera, targeted towards diabetes; Eraxis for fungal infections; Chantix, indicated for

Global pharmaceutical sales up 7 pct in '06-report  -  Mar 20, 2007
Financial Express,Inc. Some new drugs stumbled out of the gate, IMS said, including Pfizer's inhaled insulin, Exubera, which faced reimbursement issues, and Sanofi-Aventis

Lilly CEO: 2007 Zyprexa sales seen flat  -  Mar 14, 2007
MarketWatch...remains optimistic about its planned inhaled insulin product, despite Pfizer's perceived difficulties in launching a similar product, called Exubera.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional